

eTable 4. Characteristics of Infants, Stratified by Completion of the 12-Month Outcome Examination

	Completing N=98		Not Completing N=22	
	N	%	N	%
Sex				
Female	40	41%	9	41%
Race/Ethnicity				
White	51	52%	14	64%
Black/African American	16	16%	3	14%
Hispanic or Latino	14	14%	3	14%
Asian/American Indian/Alaskan Native/Hawaiian	7	7%	1	5%
More than one race	3	3%	1	5%
Unknown/not reported	7	7%	0	0%
Gestational Age (weeks)				
Mean (SD)	24.9 (1.7)		24.8 (1.3)	
Median (quartiles)	24.8 (23.7, 25.6)		24.2 (23.9, 25.9)	
Initial Intravitreal Bevacizumab Dose in Study Eye (mg)				
0.002	21	21%	3	14%
0.004	10	10%	2	9%
0.008	8	8%	1	5%
0.016	13	13%	1	5%
0.031	6	6%	4	18%
0.063	16	16%	8	36%
0.125	13	13%	3	14%
0.25	11	11%	0	0%
Stage of ROP in Study Eye at Baseline				
Stage 2 or 3 in Zone II with Plus Disease	54	55%	10	45%
Stage 3 in Zone I w/o Plus Disease	17	17%	3	14%
Any Stage in Zone I with Plus Disease	27	28%	9	41%
Birth Weight (gm)				
Mean (SD)	698 (302)		638 (154)	
Median (quartiles)	646 (545, 740)		590 (545, 700)	
Pre-existing Medical Conditions Related to Neurodevelopment^a				
Yes	31	32%	5	23%
Corrected Age at Time of 12-Month Exam (days)				
Mean (SD)	377 (47)		n/a	
Median (quartiles)	366 (357, 379)			
Range	203-542			

^a Pre-existing conditions that could impact neurodevelopmental milestones, such as intraventricular hemorrhage, periventricular leukomalacia, and hydrocephalus.